Pharsight Strengthens Senior Management Team

Wednesday, April 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

MOUNTAIN VIEW, Calif., April 29 PharsightCorporation (Nasdaq: PHST), a leading provider of software, strategicconsulting, and regulatory services for optimizing clinical drug development,today announced that it has expanded its management team by appointing John E.Murphy, DrPH, as Senior Vice President of Consulting Services. In this role,Dr. Murphy will lead the Company's two global scientific consulting unitsfocused on the strategic application of model-based drug development andregulatory-compliant PK/PD analysis and reporting services.

Dr. Murphy brings more than 25 years of pharmaceutical industry services,software and strategic management experience to the Pharsight executive team.Prior to joining Pharsight, Dr. Murphy was Principal and Executive Advisor atBooz Allen Hamilton, Inc., where he worked with leading pharmaceutical,biotechnology and high-technology companies developing strategies andimplementing solutions to improve R&D productivity. Before this, Dr. Murphyserved as Vice President and Chief Information Officer at CuraGen Corporation,a publicly traded biopharmaceutical company. While at CuraGen, he directedbusiness development and information technology services for the company andits pharmaceutical partners and clinical trials network.

"Pharsight's modeling and simulation methodology and accompanying softwaresolutions are on the leading edge of traditional drug development processesand are continuing to gain mindshare in the industry," said Dr. Murphy. "Ilook forward to working with the senior management team and its world-classscientific consulting groups to further strengthen Pharsight's serviceofferings that address the growing needs of pharmaceutical and biotechnologycompanies to more efficiently develop their pipeline of products."

"John's extensive pharmaceutical industry background and experience withcompanies focused on enabling services and technology for pharmaceuticaldevelopment will allow him to contribute meaningfully to Pharsight's futuregrowth," said Shawn O'Connor, president, chief executive officer and chairmanof Pharsight. "We believe John's leadership of both Pharsight's scientificconsulting units, Strategic Consulting Services (SCS) and Reporting andAnalysis Services (RAS), will be particularly valuable as we execute on ourplans to expand these teams' capabilities, leverage our industry-leadingsoftware, and further enhance the services that we provide to our clients toimprove drug development productivity and decision-making. We are very excitedto welcome John to Pharsight."

Prior to joining CuraGen, Dr. Murphy was founder and chief executiveofficer at Just Medicine Incorporated, a developer of regulatory-compliantclinical software for the management of real-time data collection and analysis.He was instrumental in the eventual sale of Just Medicine Incorporated and itsclinical network to a joint venture formed by two leading globalpharmaceutical companies. Dr. Murphy has also held a number of other seniorleadership roles in medical device companies, life sciences softwaretechnology companies and healthcare delivery organizations, including PredictIncorporated, Community Health Computing and Mercy Hospital in Watertown, NewYork.

Before Dr. Murphy began his career in the pharmaceutical industry, he heldsenior health care policy management and research positions at the SloanCommission on Government and Higher Education in Washington, DC, at theMassachusetts Institute of Technology, and with the Health Planning Councilfor Greater Boston. He has lectured on numerous life sciences technology andpharmaceutical research topics, and has authored journal articles inpublications such as Health Care Informatics and the New England Journal ofMedicine. He is also the author of 17 patents, including 12 approved orpending patents on clinical software and data mining techniques.

Dr. Murphy earned hi

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store